UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000002188
Receipt number R000002687
Scientific Title Comparative study of efficacy and safety of Administering 4mg once daily and 2mg twice daily of silodosin in patients with benign prostatic hyperplasia
Date of disclosure of the study information 2009/08/01
Last modified on 2009/07/13 11:15:50

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comparative study of efficacy and safety of Administering 4mg once daily and 2mg twice daily of silodosin in patients with benign prostatic hyperplasia

Acronym

Comparative study of mode of administration of silodosin

Scientific Title

Comparative study of efficacy and safety of Administering 4mg once daily and 2mg twice daily of silodosin in patients with benign prostatic hyperplasia

Scientific Title:Acronym

Comparative study of mode of administration of silodosin

Region

Japan


Condition

Condition

benign prostatic hyperplasia

Classification by specialty

Urology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and safety of administered silodosin 4mg once daily

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change and change rate of I-PSS total score,subscore

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Silodosin 4mg once daily

Interventions/Control_2

Silodosin 2mg twice daily

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male

Key inclusion criteria

Man with benign prostatic hyperplasia who treated by tamsulosin or naftpidil,and to fill the following items
1.I-PSS total score:over 8 points
2.QOL score:over 4 points

Key exclusion criteria

1.Men who treated by the medicin that has possibility to influence the urination function
2.prostatic cancer
3.Urinary tract infection
4.urolithiasis
5.hepatic dysfunction, renal dysfunction, cardiac disease
6.orthostatic hypotention
7.Any other clinically relevant laboratory abnormality as judged by the investigator

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kunitaro Sanuki

Organization

JR Tokyo General Hospital

Division name

Urology

Zip code


Address

2-1-3,Yoyogi,Shibuya-ku,Tokyo,Japan

TEL

03-3320-2200

Email



Public contact

Name of contact person

1st name
Middle name
Last name Kunitaro Sanuki

Organization

JR Tokyo General Hospital

Division name

Urology

Zip code


Address

2-1-3,Yoyogi,Shibuya-ku,Tokyo,Japan

TEL

03-3320-2200

Homepage URL


Email

sanuki@jreast.co.jp


Sponsor or person

Institute

JR Tokyo General Hospital

Institute

Department

Personal name



Funding Source

Organization

Daiichi-Sankyo

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2009 Year 08 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2009 Year 06 Month 19 Day

Date of IRB


Anticipated trial start date

2009 Year 08 Month 01 Day

Last follow-up date

2010 Year 12 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2009 Year 07 Month 13 Day

Last modified on

2009 Year 07 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002687


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name